Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.
Botanix Pharmaceuticals has completed an employee share scheme buy-back of 6,928,586 ordinary fully paid shares, as disclosed in its final buy-back notification to the ASX dated 30 December 2025. The transaction, recorded with zero consideration payable, appears to be a technical or administrative cancellation of securities under an employee scheme, modestly tightening the company’s share base and potentially affecting equity allocation among existing shareholders without implying a cash outlay by the company.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an ASX-listed pharmaceutical company (code BOT) focused on developing and commercialising therapeutics, with its securities traded as ordinary fully paid shares on the Australian Securities Exchange.
Average Trading Volume: 5,606,992
Technical Sentiment Signal: Sell
Current Market Cap: A$237M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.